$TWST

Cho Dennis sold $1.8M of TWST

Cho Dennis (See Remarks) sold 14,205 shares of Twist Bioscience Corp (TWST) at $129.75 ($1.84M total) on 2026-08-19 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cho Dennis
Published Aug 21, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TWST
Bearish
medium confidence
Mentioned
$TWST
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider holdings and may influence short‑term trading decisions.

02

Market read

Insider sales are closely watched by traders; this $1.8M sale is material for TWST.

03

What to watch

Potential upcoming financing needs or tax planning could be driving the sale.

Relevance 5/10Novelty 7/10Timing: today

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources of new information.

Company-level read

Ticker impact

$TWSTBearishMedium confidence
Context

Officer Cho Dennis sold 14,205 shares of Twist Bioscience for $1.84M via a 10b5‑1 plan.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

The sale size ($1.8M) is material for a mid‑cap biotech and was executed through a pre‑arranged plan, suggesting a neutral to slightly bearish signal.

Market effects

May prompt scrutiny of insider activity across biotech peers.

Limited to US biotech sector.

Low global impact.

Counterpoint

The sale was pre‑arranged under a 10b5‑1 plan and may not reflect current sentiment.

Key entities

  • Twist Bioscience Corp

    US‑listed biotech company (NASDAQ: TWST).

  • Cho Dennis

    Company officer executing a 10b5‑1 sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MRNAHighAI 9/10

Bond Jitters Meet Biotech Fireworks

Bond market volatility pressured stocks early in the week, with the Nasdaq dropping 2.1%. Biotech stocks surged: Moderna (MRNA) rose 177% after positive cancer trial results, and Twist Bioscience (TWST) gained 23% on AI-driven protein binder success. NVIDIA's earnings and the Jackson Hole symposium are upcoming market tests.

$TWSTHighAI 8/10

Twist Bioscience Stock Surges As Anthropic AI Deal And Upbeat Guidance Reset Outlook

Twist Bioscience (TWST) stock rose 6.79% on strong investor optimism. The company reported Q3 revenue of $118.4M, up 23% YoY, with a 78% gross margin but negative EBIT margin and ROE. Guidance was raised to $456M-$457M for FY26, with Q4 adjusted EBITDA breakeven expected. The stock has seen strong technical performance, with resistance near $150 and support at $130-$135.

$TWSTHighAI 8/10

Why is Twist Bioscience stock surging today?

Twist Bioscience (TWST) stock rose 15.3% after Anthropic's research highlighted its role in producing AI-designed proteins. The company filed an 8-K disclosing the collaboration, which supports its AI-driven drug discovery growth narrative. Shares reached a 52-week high of $141.10.